Methylprednisolone injection is a corticosteroid used to treat a variety of conditions, including inflammatory disorders, allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, and respiratory diseases [1]. It is also used to induce diuresis or remission of proteinuria in certain cases of nephrotic syndrome [1].
What specific conditions can methylprednisolone injection treat?
Methylprednisolone injection is indicated for the treatment of conditions such as severe or incapacitating allergic states that do not respond to conventional treatment, including seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, and atopic dermatitis [1]. It is also used for rheumatic disorders, lupus erythematosus, and psoriatic arthritis [1]. In dermatologic conditions, it can treat pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, and mycosis fungoides [1]. For endocrine disorders, it may be used in primary or secondary adrenocortical insufficiency [1]. Gastrointestinal diseases that can be treated include ulcerative colitis and regional enteritis [1]. Hematologic disorders like idiopathic thrombocytopenic purpura in adults, acquired (autoimmune) hemolytic anemia, and erythroblastopenia are also indications [1]. Methylprednisolone is used in the management of leukemias and lymphomas in adults, as well as in palliative management of leukemias and lymphomas of childhood [1]. Nervous system conditions include acute exacerbations of multiple sclerosis [1]. Ophthalmic diseases like sympathetic ophthalmia, allergic marginal corneal ulcers, and anterior segment inflammation are treated with methylprednisolone injection [1]. Renal diseases such as lupus nephritis and certain cases of nephrotic syndrome are also indications [1]. Respiratory diseases include symptomatic sarcoidosis and berylliosis [1].
How does methylprednisolone injection work?
Methylprednisolone is a synthetic glucocorticoid that suppresses inflammation and immune responses by inhibiting the migration of polymorphonuclear leukocytes and reversing capillary permeability [1]. It also inhibits the synthesis of prostaglandins, which are potent mediators of inflammation [1].
What are the potential side effects of methylprednisolone injection?
Common side effects include fluid and electrolyte disturbances, muscle weakness, impaired wound healing, amenorrhea, and secondary adrenocortical and pituitary unresponsiveness [1]. More serious side effects can include hyperglycemia, osteoporosis, vertebral compression fractures, aseptic necrosis of the femoral and humeral heads, and gastrointestinal perforation or hemorrhage [1]. Patients may also experience increased susceptibility to infection, peptic ulceration, and behavioral or mood changes [1].
How is methylprednisolone injection administered?
Methylprednisolone acetate for injection is available for intramuscular, intravenous, intra-articular, and intralesional administration [1]. Dosage and administration depend on the condition being treated and the severity of the symptoms [1].
When does the patent for methylprednisolone expire?
Methylprednisolone is a well-established medication, and its original patents have long since expired, allowing for the availability of generic versions [2]. DrugPatentWatch.com tracks patent information for drugs, but for older, off-patent medications like methylprednisolone, the focus is on any new patents for formulations or delivery methods [2].
Are there alternative treatments for conditions treated by methylprednisolone injection?
Alternative treatments depend on the specific condition being managed. For inflammatory and autoimmune conditions, other corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic agents may be considered [3]. For allergic reactions, antihistamines and decongestants are common alternatives [4]. Treatment decisions are individualized based on the patient's condition, severity, and response to therapy [3, 4].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011339s061lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/diagnosis-treatment/drc-20352563
[4] https://www.mayoclinic.org/diseases-conditions/allergies/diagnosis-treatment/drc-20351142